When qualified institutions seek to purchase CJC-1295 for laboratory research, securing high-purity reagents with complete analytical verification is essential. As a synthetic growth-hormone-releasing hormone (GHRH) analog, CJC-1295 is widely studied for its ability to extend the half-life of GHRH receptor signaling and sustain downstream IGF-1 expression in preclinical models. PX1 Research provides analytical-grade CJC-1295 manufactured in GMP-compliant, USA-based facilities, verified by lot-specific mass spectrometry and HPLC testing.
When qualified institutions seek to purchase CJC-1295 for laboratory research, securing high-purity reagents with complete analytical verification is essential. As a synthetic growth-hormone-releasing hormone (GHRH) analog, CJC-1295 is widely studied for its ability to extend the half-life of GHRH receptor signaling and sustain downstream IGF-1 expression in preclinical models. PX1 Research provides analytical-grade CJC-1295 manufactured in GMP-compliant, USA-based facilities, verified by lot-specific mass spectrometry and HPLC testing.
Investigators looking to purchase CJC-1295 for laboratory research require high-purity, analytically verified reagents to ensure experimental reproducibility across in vitro and animal assays. CJC-1295 is a synthetic 29-amino-acid tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion and sustain downstream insulin-like growth factor 1 (IGF-1) expression for tissue repair research.
Acquiring research-grade CJC-1295 demands strict validation standards. Variations in peptide synthesis, residual trifluoroacetic acid (TFA) content, or moisture contamination can skew receptor affinity measurements and cellular response assays. PX1 Research supplies analytical-grade reagents manufactured in USA facilities, supported by independent third-party certification per lot to meet rigorous laboratory requirements.
CJC-1295 is classified within the peptide class of growth hormone-releasing hormone (GHRH) mimetics. Its primary structure is derived from the functional N-terminal region of native human GHRH (1-29), incorporating targeted amino acid substitutions at positions 2, 8, 15, and 27. These modification sites—specifically D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27—confer enhanced enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) degradation.
In physiological buffers, native GHRH exhibits a rapid plasma half-life of less than twelve minutes due to cleavage between Tyr1 and Ala2 by DPP-IV. By replacing L-alanine with D-alanine at position 2, the enzymatic cleavage site is stericly hindered, dramatically reducing clearance rates in preclinical models. To explore broader structural variations within this peptide family, researchers can consult our comprehensive GHRH analogs guide in the PX1 reference portal.
In published literature, CJC-1295 appears in two primary variants: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (frequently designated as Modified GRF 1-29). Understanding the chemical distinctions between these variants is critical prior to experimental setup.
The DAC modification consists of a reactive maleimido derivative attached via a lysine linker at the C-terminus. When introduced into serum-containing media or living tissue, the maleimido group forms a stable covalent bond with circulating albumin at the Cys34 residue. This albumin-binding mechanism extends the peptide's circulating half-life from hours to several days in animal models, resulting in sustained GH elevation. Conversely, modified GRF 1-29 lacks the maleimido complex, producing shorter, pulsatile GH release kinetics that closely mirror endogenous GHRH secretion. Laboratories evaluating these distinct kinetic profiles can review our CJC-1295 DAC product page alongside the non-conjugated variant available at CJC-1295 No DAC.
At the cellular level, CJC-1295 functions as a selective agonist at the GHRH receptor (GHRHR), a class B G-protein coupled receptor located on somatotroph cells in the anterior pituitary gland. Ligand binding to GHRHR activates the heterotrimeric Gs protein alpha subunit, triggering intracellular adenylate cyclase activity.
Accumulation of intracellular cyclic adenosine monophosphate (cAMP) subsequently activates Protein Kinase A (PKA). PKA phosphorylates specific transcription factors, including cAMP response element-binding protein (CREB), which upregulates GH gene transcription and stimulates exocytosis of stored GH granules. In vitro assays demonstrate that sustained GHRHR activation by CJC-1295 induces a dose-dependent increase in GH synthesis without downregulating receptor sensitivity or depleting pituitary somatotroph reserves.
Preclinical studies in rodent models and non-human primates indicate that CJC-1295 administration alters baseline endocrinological profiles by elevating total area-under-the-curve (AUC) for serum growth hormone and IGF-1. Early animal studies reported mean plasma concentration half-lives exceeding 6 days for DAC-bound formulations, preserving physiological pulsatility while increasing mean basal levels.
The downstream consequences of sustained GHRH pathway stimulation center on hepatic IGF-1 synthesis. Systemic IGF-1 acts as the primary mediator of GH-driven tissue growth, cellular proliferation, and extracellular matrix remodeling. In vivo data indicate that CJC-1295 sustains baseline IGF-1 levels without inducing acute hyperinsulinemia, making it a valuable target for investigating somatotrophic influence on cellular metabolic kinetics.
Laboratory investigations utilizing CJC-1295 primarily focus on cellular repair mechanisms, skeletal muscle protein synthesis, and collagen deposition in wound healing models. Because IGF-1 directly promotes satellite cell proliferation and differentiation, GHRH agonists are frequently deployed in muscle injury research to observe satellite cell dynamics following mechanical strain.
Furthermore, preclinical research models examine how CJC-1295 influences lipid oxidation and cellular energy expenditure. In vitro adipocyte cultures treated with GHRH secretagogues demonstrate altered lipolytic signaling pathway activation, supporting research into metabolic homeostasis, nitrogen retention, and extracellular matrix maintenance. Investigators interested in broader endocrine research paradigms can access the complete PX1 research library hub.
Within preclinical secretagogue research, CJC-1295 is frequently evaluated alongside alternative peptides that stimulate the GH axis through distinct or complementary receptor pathways. Comparing these compounds helps researchers design multi-target peptide assays.
While CJC-1295 targets the GHRH receptor to stimulate GH transcription, ghrelin receptor agonists such as Ipamorelin target the growth hormone secretagogue receptor (GHSR-1a), acting synergistically with GHRH analogs to amplify pulsatile GH release. Meanwhile, Sermorelin represents the un-modified 29-amino-acid GHRH sequence, exhibiting rapid clearance compared to the extended degradation resistance of CJC-1295. To review PX1's full inventory of secretagogues and structural analogs, visit our main all peptides catalog.
When procuring reagents for quantitative research, verifying supplier quality is vital to prevent experimental errors caused by degraded or contaminated compounds. Low-grade peptides often contain truncated sequences, deletion peptides, or residual organic solvents that introduce confounding variables into bioassays.
PX1 Research enforces strict quality assurance protocols for every lot of CJC-1295. Synthesis takes place in GMP-compliant, USA-based facilities adhering to rigorous quality management systems. Every production batch undergoes independent analytical verification at an ISO 17025 accredited laboratory, utilizing High-Performance Liquid Chromatography (RP-HPLC) for purity determination and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF-MS) or LC-MS for molecular mass verification.
Additionally, PX1 conducts Chromogenic Limulus Amebocyte Lysate (LAL) testing on every lot to guarantee endotoxin levels remain below strict laboratory limits (<0.05 EU/mg). Fully transparent, lot-specific Certificates of Analysis (COAs) containing raw chromatograms and mass spectra are available for verification prior to purchase.
Proper handling procedures are essential to preserve the structural integrity of CJC-1295 in laboratory settings. Lyophilized CJC-1295 should be stored in commercial freezer units at -20°C or -80°C upon arrival, shielded from direct light exposure to prevent oxidative degradation.
For reconstitution, use aseptic laboratory practices within a laminar flow hood. Bacteriostatic Water (0.9% benzyl alcohol) or sterile deionized water should be introduced slowly along the glass wall of the vial to minimize shear stress on the peptide lattice. Gentle swirling is recommended; vigorously shaking the vial can cause aggregation or tertiary conformational changes. Reconstituted CJC-1295 solutions should be stored at 2°C to 8°C and used within 30 days, or aliquoted into single-use micro-centrifuge tubes and frozen at -80°C to avoid repeated freeze-thaw cycles. Institutional buyers seeking volume procurement for long-term study protocols can apply for institutional pricing via our wholesale lab account portal.
What is the primary mechanism of CJC-1295 in preclinical research?
CJC-1295 acts as a synthetic GHRH receptor agonist. It binds to GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate growth hormone synthesis and secretion, which subsequently elevates baseline IGF-1 levels in study models.
How does CJC-1295 with DAC differ from CJC-1295 without DAC?
CJC-1295 with DAC contains a maleimido derivative attached to a C-terminal lysine, allowing it to form covalent bonds with circulating serum albumin. This extends its clearance half-life significantly. CJC-1295 without DAC (Modified GRF 1-29) lacks this complex, resulting in a shorter half-life that induces pulsatile GH release.
What purity levels are required for CJC-1295 in laboratory bioassays?
Quantitative research assays typically require peptide purity of 98.0% or higher, as determined by RP-HPLC. PX1 Research provides CJC-1295 verified at ≥98% purity with lot-specific mass spectrometry and HPLC chromatograms included in every COA.
How are endotoxin levels tested for PX1 Research peptides?
Every lot of CJC-1295 undergoes Limulus Amebocyte Lysate (LAL) testing to confirm that bacterial endotoxin levels fall below strict research thresholds (typically <0.05 EU/mg), ensuring compatibility with sensitive cell cultures and in vivo assays.
How should CJC-1295 be reconstituted for in vitro experiment preparation?
CJC-1295 should be reconstituted under sterile conditions using sterile or bacteriostatic water. Direct liquid stream impact should be avoided by aiming at the inner vial wall, followed by gentle swirling without shaking to prevent peptide aggregation.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities. Orders are fulfilled directly from distribution centers in California and Arizona with same-day shipping on standard business days.
What storage conditions maintain CJC-1295 stability long term?
Lyophilized CJC-1295 powder should be stored long term at -20°C to -80°C. Reconstituted liquid aliquots should be kept refrigerated at 2–8°C for short-term use or frozen at -80°C to prevent hydrolysis.
Can CJC-1295 be co-administered with GHS-R agonists in study protocols?
Yes, literature frequently investigates dual-agonist models combining GHRH analogs like CJC-1295 with ghrelin mimetics like Ipamorelin to observe additive or synergistic GH secretion dynamics via complementary receptor pathways.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.